<?xml version="1.0" encoding="UTF-8"?>
<p>Because CHIKV infection produces a life-lasting protection against a second infection and due to the limited antigenic variability of the virus, one might think that a CHIKV vaccine should be relatively easy to produce, or at least easier so than a dengue virus vaccine [
 <xref rid="B204-microorganisms-07-00133" ref-type="bibr">204</xref>]. Nevertheless, there are still no licensed CHIKV vaccines available, although many candidates have been tested including live-attenuated vaccines [
 <xref rid="B205-microorganisms-07-00133" ref-type="bibr">205</xref>,
 <xref rid="B206-microorganisms-07-00133" ref-type="bibr">206</xref>], recombinant virus vaccines (measles virus [
 <xref rid="B207-microorganisms-07-00133" ref-type="bibr">207</xref>,
 <xref rid="B208-microorganisms-07-00133" ref-type="bibr">208</xref>,
 <xref rid="B209-microorganisms-07-00133" ref-type="bibr">209</xref>], vesicular stomatitis virus [
 <xref rid="B210-microorganisms-07-00133" ref-type="bibr">210</xref>,
 <xref rid="B211-microorganisms-07-00133" ref-type="bibr">211</xref>]), inactivated vaccines [
 <xref rid="B212-microorganisms-07-00133" ref-type="bibr">212</xref>,
 <xref rid="B213-microorganisms-07-00133" ref-type="bibr">213</xref>], virus-like particles (VLPs) [
 <xref rid="B214-microorganisms-07-00133" ref-type="bibr">214</xref>,
 <xref rid="B215-microorganisms-07-00133" ref-type="bibr">215</xref>,
 <xref rid="B216-microorganisms-07-00133" ref-type="bibr">216</xref>], DNA- [
 <xref rid="B217-microorganisms-07-00133" ref-type="bibr">217</xref>,
 <xref rid="B218-microorganisms-07-00133" ref-type="bibr">218</xref>] or mRNA-based vaccines [
 <xref rid="B219-microorganisms-07-00133" ref-type="bibr">219</xref>], and subunit formulations of CHIKV [
 <xref rid="B220-microorganisms-07-00133" ref-type="bibr">220</xref>].
</p>
